Policosanol Research includes well designed clinical trials involving nearly 30,000 patients. The research includes:
How It Works:
Along with a dietary therapy, Policosanol helps decrease elevated serum total and low density lipoprotein (LDL) cholesterol and increase high density lipoprotein (HDL) cholesterol that prevents coronary heart disease.
Medical Benefits
Clinical Efficacy
Policosanol is an agent to lower cholesterol with exceptional clinical documentation demonstrating efficacy, safety, and tolerability in patients with type 2 hypercholesterolemia and inpatients with secondary hypercholesterolemia associated with diabetis or nephrotic syndrome.
Safety & Toxicology
Policosanol exhibits an exemplary safety profile in all controlled studies. Animal. Policosanol research studies is virtually non toxic as the oral LD50 in rats, mice, rabbits, and dogs was > 5000mg/kg. Side effects were comparable to placebo, policosanol has exerted no negative effect of any clinical or laboratory parameter.
- short and long term randomized double-blind studies comparing policosanol to a placebo as well as...
- blind comparative trials versus statin drugs, fibrates, niacin and probucol.
How It Works:
Along with a dietary therapy, Policosanol helps decrease elevated serum total and low density lipoprotein (LDL) cholesterol and increase high density lipoprotein (HDL) cholesterol that prevents coronary heart disease.
Medical Benefits
- Helps maintain healthy cholesterol levels in different tissue such as liver, kidney and fatty tissues.
- Helps reduce platelet agregation by altering prostaglandin synthesis and can be used as an alternative for aspirin.
- Helps reduce the risk of myocardial infarction (MI) commonly known as heart attack.
- Helps reduce the risk of angina, fatal and non-fatal stroke.
- It is an effective antioxidant in preventing LDL oxidation.
- Liver friendly and safe for diabetic patients.
Clinical Efficacy
Policosanol is an agent to lower cholesterol with exceptional clinical documentation demonstrating efficacy, safety, and tolerability in patients with type 2 hypercholesterolemia and inpatients with secondary hypercholesterolemia associated with diabetis or nephrotic syndrome.
Safety & Toxicology
Policosanol exhibits an exemplary safety profile in all controlled studies. Animal. Policosanol research studies is virtually non toxic as the oral LD50 in rats, mice, rabbits, and dogs was > 5000mg/kg. Side effects were comparable to placebo, policosanol has exerted no negative effect of any clinical or laboratory parameter.
RSS Feed